DEF: Avanos Medical Seeks Stockholder Approval for Incentive Plan Amendment at 2025 Annual Meeting

Avanos Medical is asking stockholders to approve an amendment to its 2021 Long Term Incentive Plan to increase the number of shares available for issuance by 2,250,000 at the upcoming annual meeting.

Summary

• Avanos Medical is holding its 2025 Annual Meeting of Stockholders on April 24, 2025, at its headquarters in Alpharetta, Georgia.
• Stockholders will vote on electing five directors, ratifying the appointment of Deloitte & Touche LLP as independent auditors, approving executive compensation, and approving an amendment to the 2021 Long Term Incentive Plan.
• The key proposal is to amend the 2021 Long Term Incentive Plan to increase the number of shares of common stock reserved for issuance by 2,250,000 shares.
• The Board of Directors recommends voting FOR all proposals.
• The company believes the current number of shares available under the plan is insufficient for future equity grants to key employees, consultants, and advisors.
• As of February 28, 2025, approximately 788,487 shares were available for future awards under the 2021 Plan.
• If approved, the amendment would increase the available shares to approximately 3,038,487 shares.
• The company estimates this increase would cover equity incentive awards for approximately two years.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining the proposals for the annual meeting. The recommendation to vote FOR the proposals suggests a positive outlook from management, but the overall tone is neutral.

Positives

• Approval of the amendment will enable the company to continue making equity compensation grants.
• The company believes it has been judicious in its share usage under the Prior Plan and the 2021 Plan.
• The company aims to align the interests of its employees with stockholders through equity compensation.

Negatives

• If the proposal is approved, the company's overhang would increase from approximately 5.1% to approximately 9.3%.

Risks

• If the amendment is not approved, the company may face challenges in attracting and retaining key personnel.
• The company may need to offer additional cash-based incentives if equity compensation is limited.

Future Outlook

The company expects that the additional shares, combined with existing available shares and potential forfeitures, should satisfy equity compensation needs for approximately two years.

Management Comments

• The Compensation Committee believes the number of shares available for future awards under the 2021 Plan will not be sufficient to make the grants it believes will be needed over the next few years to provide adequate long-term equity incentives to our key employees, consultants, and advisors.
• Considering our historical grant practices, the Company believes it have been judicious in its share usage under the Prior Plan and the 2021 Plan, and mindful of potential stockholder dilution.

Industry Context

Equity incentive plans are a common tool used by public companies to attract, retain, and motivate employees. The specific terms of these plans, including the number of shares authorized and the types of awards granted, vary depending on the company's size, industry, and compensation philosophy.

Comparison to Industry Standards

• The company's burn rate of 1.63% is a metric used to evaluate the rate at which a company is depleting its shares reserved for issuance under its equity compensation plans.
• Overhang, which is expected to increase to 9.3% if the proposal is approved, is a measure of the potential dilution to existing shareholders from equity compensation plans.
• These metrics are often compared to industry averages and peer companies to assess the competitiveness and potential impact of the company's equity compensation program.

Stakeholder Impact

• Approval of the amendment could positively impact employees by providing them with equity incentives.
• Stockholders could be impacted by potential dilution if the amendment is approved.

Next Steps

• Stockholders to vote on the proposed amendment at the 2025 Annual Meeting.
• Company to register the additional shares authorized for issuance under the amended 2021 Plan under the Securities Act of 1933.

Key Dates